Literature DB >> 25998914

Type I interferonopathies--an expanding disease spectrum of immunodysregulation.

Min Ae Lee-Kirsch1, Christine Wolf, Stefanie Kretschmer, Axel Roers.   

Abstract

Type I interferons (IFNs) play a central role in the immune defense against viral infections. Type I IFN signaling is activated by pattern recognition receptors upon sensing of viral nucleic acids and induces antiviral programs through modulation of innate and adaptive immune responses. Type I interferonopathies comprise a heterogenous group of genetically determined diseases that are characterized by inappropriate activation of type I IFN. While their phenotypic spectrum is broad, ranging from severe neurological impairment to mild cutaneous disease, systemic autoinflammation, and autoimmunity are commonly shared signs of type I interferonopathies. Although the mechanisms underlying various disease phenotypes associated with inappropriate type I IFN activation have yet to be fully elucidated, our current understanding of the molecular pathogenesis of type I interferonopathies has provided a set of candidate molecules that can be interrogated in search of targeted therapies.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25998914     DOI: 10.1007/s00281-015-0500-x

Source DB:  PubMed          Journal:  Semin Immunopathol        ISSN: 1863-2297            Impact factor:   11.759


  78 in total

Review 1.  A weak signal for strong responses: interferon-alpha/beta revisited.

Authors:  T Taniguchi; A Takaoka
Journal:  Nat Rev Mol Cell Biol       Date:  2001-05       Impact factor: 94.444

2.  Requirement of the RNA editing deaminase ADAR1 gene for embryonic erythropoiesis.

Authors:  Q Wang; J Khillan; P Gadue; K Nishikura
Journal:  Science       Date:  2000-12-01       Impact factor: 47.728

3.  Familial Aicardi-Goutières syndrome due to SAMHD1 mutations is associated with chronic arthropathy and contractures.

Authors:  Russell C Dale; Hannah Gornall; Davinder Singh-Grewal; Melanie Alcausin; Gillian I Rice; Yanick J Crow
Journal:  Am J Med Genet A       Date:  2010-04       Impact factor: 2.802

4.  SAMHD1 is a nucleic-acid binding protein that is mislocalized due to aicardi-goutières syndrome-associated mutations.

Authors:  Adriana Goncalves; Evren Karayel; Gillian I Rice; Keiryn L Bennett; Yanick J Crow; Giulio Superti-Furga; Tilmann Bürckstümmer
Journal:  Hum Mutat       Date:  2012-04-16       Impact factor: 4.878

5.  TREX1 deficiency triggers cell-autonomous immunity in a cGAS-dependent manner.

Authors:  Andrea Ablasser; Inga Hemmerling; Jonathan L Schmid-Burgk; Rayk Behrendt; Axel Roers; Veit Hornung
Journal:  J Immunol       Date:  2014-05-09       Impact factor: 5.422

6.  A progressive familial encephalopathy in infancy with calcifications of the basal ganglia and chronic cerebrospinal fluid lymphocytosis.

Authors:  J Aicardi; F Goutières
Journal:  Ann Neurol       Date:  1984-01       Impact factor: 10.422

7.  Phosphorylation of SAMHD1 by cyclin A2/CDK1 regulates its restriction activity toward HIV-1.

Authors:  Alexandra Cribier; Benjamin Descours; Ana Luiza Chaves Valadão; Nadine Laguette; Monsef Benkirane
Journal:  Cell Rep       Date:  2013-04-17       Impact factor: 9.423

8.  Assessment of interferon-related biomarkers in Aicardi-Goutières syndrome associated with mutations in TREX1, RNASEH2A, RNASEH2B, RNASEH2C, SAMHD1, and ADAR: a case-control study.

Authors:  Gillian I Rice; Gabriella M A Forte; Marcin Szynkiewicz; Diana S Chase; Alec Aeby; Mohamed S Abdel-Hamid; Sam Ackroyd; Rebecca Allcock; Kathryn M Bailey; Umberto Balottin; Christine Barnerias; Genevieve Bernard; Christine Bodemer; Maria P Botella; Cristina Cereda; Kate E Chandler; Lyvia Dabydeen; Russell C Dale; Corinne De Laet; Christian G E L De Goede; Mireia Del Toro; Laila Effat; Noemi Nunez Enamorado; Elisa Fazzi; Blanca Gener; Madli Haldre; Jean-Pierre S-M Lin; John H Livingston; Charles Marques Lourenco; Wilson Marques; Patrick Oades; Pärt Peterson; Magnhild Rasmussen; Agathe Roubertie; Johanna Loewenstein Schmidt; Stavit A Shalev; Rogelio Simon; Ronen Spiegel; Kathryn J Swoboda; Samia A Temtamy; Grace Vassallo; Catheline N Vilain; Julie Vogt; Vanessa Wermenbol; William P Whitehouse; Doriette Soler; Ivana Olivieri; Simona Orcesi; Mona S Aglan; Maha S Zaki; Ghada M H Abdel-Salam; Adeline Vanderver; Kai Kisand; Flore Rozenberg; Pierre Lebon; Yanick J Crow
Journal:  Lancet Neurol       Date:  2013-10-30       Impact factor: 44.182

9.  Inherited STING-activating mutation underlies a familial inflammatory syndrome with lupus-like manifestations.

Authors:  Nadia Jeremiah; Bénédicte Neven; Matteo Gentili; Isabelle Callebaut; Sophia Maschalidi; Marie-Claude Stolzenberg; Nicolas Goudin; Marie-Louis Frémond; Patrick Nitschke; Thierry J Molina; Stéphane Blanche; Capucine Picard; Gillian I Rice; Yanick J Crow; Nicolas Manel; Alain Fischer; Brigitte Bader-Meunier; Frédéric Rieux-Laucat
Journal:  J Clin Invest       Date:  2014-11-17       Impact factor: 14.808

10.  A mutation in TREX1 that impairs susceptibility to granzyme A-mediated cell death underlies familial chilblain lupus.

Authors:  Min Ae Lee-Kirsch; Dipanjan Chowdhury; Scott Harvey; Maoliang Gong; Lydia Senenko; Kerstin Engel; Christiane Pfeiffer; Thomas Hollis; Manfred Gahr; Fred W Perrino; Judy Lieberman; Norbert Hubner
Journal:  J Mol Med (Berl)       Date:  2007-04-18       Impact factor: 5.606

View more
  15 in total

Review 1.  [Neuroimmunology and rheumatology: overlap and differential diagnoses].

Authors:  C Trebst; T Kümpfel
Journal:  Nervenarzt       Date:  2018-10       Impact factor: 1.214

Review 2.  [Familial chilblain lupus : Type 1 interferonopathy with model character].

Authors:  C Fiehn
Journal:  Z Rheumatol       Date:  2017-05       Impact factor: 1.372

3.  Nucleic acid-mediated autoinflammation and autoimmunity-type I interferonopathies.

Authors:  Min Ae Lee-Kirsch; Claudia Günther; Axel Roers
Journal:  J Mol Med (Berl)       Date:  2016-10       Impact factor: 4.599

Review 4.  Familial Chilblain Lupus - What Can We Learn from Type I Interferonopathies?

Authors:  Christoph Fiehn
Journal:  Curr Rheumatol Rep       Date:  2017-08-26       Impact factor: 4.592

Review 5.  From autoinflammation to autoimmunity: old and recent findings.

Authors:  Francesco Caso; Luisa Costa; Valeria Nucera; Giuseppe Barilaro; Ignazio Francesco Masala; Rossella Talotta; Paolo Caso; Raffaele Scarpa; Piercarlo Sarzi-Puttini; Fabiola Atzeni
Journal:  Clin Rheumatol       Date:  2018-07-16       Impact factor: 2.980

6.  Induction of the type I interferon response in neurological forms of Gaucher disease.

Authors:  Einat B Vitner; Tamar Farfel-Becker; Natalia Santos Ferreira; Dena Leshkowitz; Piyush Sharma; Karl S Lang; Anthony H Futerman
Journal:  J Neuroinflammation       Date:  2016-05-12       Impact factor: 8.322

Review 7.  Type 1 Diabetes and Type 1 Interferonopathies: Localization of a Type 1 Common Thread of Virus Infection in the Pancreas.

Authors:  Virginie S E Jean-Baptiste; Chang-Qing Xia; Michael J Clare-Salzler; Marc S Horwitz
Journal:  EBioMedicine       Date:  2017-06-21       Impact factor: 8.143

8.  Toward an Inclusive, Congruent, and Precise Definition of Autoinflammatory Diseases.

Authors:  Per Wekell; Stefan Berg; Anna Karlsson; Anders Fasth
Journal:  Front Immunol       Date:  2017-04-27       Impact factor: 7.561

Review 9.  JAK Inhibitors in Rheumatology: Implications for Paediatric Syndromes?

Authors:  S A Kerrigan; I B McInnes
Journal:  Curr Rheumatol Rep       Date:  2018-11-08       Impact factor: 4.592

10.  Identification of a small molecule that primes the type I interferon response to cytosolic DNA.

Authors:  Samira Khiar; Marianne Lucas-Hourani; Sébastien Nisole; Nikaïa Smith; Olivier Helynck; Maryline Bourgine; Claude Ruffié; Jean-Philippe Herbeuval; Hélène Munier-Lehmann; Frédéric Tangy; Pierre-Olivier Vidalain
Journal:  Sci Rep       Date:  2017-05-31       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.